Zobrazeno 1 - 10
of 447
pro vyhledávání: '"Gentili N"'
Autor:
Albiñana CB; IQVIA, London, United Kingdom., Pallocca M; IRCCS Istituto Nazionale Tumori Regina Elena, Rome, Italy., Fenton H; IQVIA, London, United Kingdom.; Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom., Sopwith W; IQVIA, London, United Kingdom.; Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom., Eden CV; IQVIA, London, United Kingdom., Akre O; Karolinska Comprehensive Cancer Center, Stockholm, Sweden., Auranen A; Tays Cancer Centre, Pirkanmaa, Finland., Bocquet F; Data Factory & Analytics Department, Institut de Cancérologie de l'Ouest, Nantes-Angers, France., Borges M; IQVIA, London, United Kingdom.; Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal., Calvo E; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain., Corkett J; Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom., Cosimo SD; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Gentili N; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Guérin J; Data Office, Institut Curie, Paris, France., Jor S; Oslo University Hospital Cancer Center, Oslo, Norway., Kazda T; Masaryk Memorial Cancer Institute, Brno, Jihomoravský, Czechia., Kolar A; Institute of Oncology Ljubljana, Ljubljana, Slovenia., Kuschel T; Charité, Universitätsmedizin Berlin, Berlin, Germany., Lostes MJ; Vall d'Hebron University Hospital, Barcelona, Spain., Paratore C; University Hospital San Luigi Gonzaga of Orbassano, Orbassano TO, Italy., Pedrazzoli P; Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia PV, Italy., Petrovic M; Sestre Milosrdnice University Hospital, Zagreb, Croatia., Raid J; Tartu University Hospital, Tartu, Tartumaa, Estonia., Roche M; Trinity St James's Cancer Institute, Dublin, Ireland., Schatz C; Biobank Innsbruck, Innsbruck, Austria., Thonnard J; Cliniques Universitaires Saint-Luc, Brussels, Belgium., Tonon G; IRCCS San Raffaele Scientific Institute, Milan, Italy., Traverso A; IRCCS San Raffaele Scientific Institute, Milan, Italy.; Maastricht Comprehensive Cancer Center, Maastricht, The Netherlands.; DIGICORE, Bruxelles, Belgium., Wolf A; University Cancer Center Frankfurt (UCT), University Hospital, Goethe University, Frankfurt, Germany., Zedan AH; Vejle Hospital, University of Southern Denmark, Vejle, Denmark., Mahon P; IQVIA, London, United Kingdom.; DIGICORE, Bruxelles, Belgium.
Publikováno v:
Applied clinical informatics [Appl Clin Inform] 2024 Aug; Vol. 15 (4), pp. 743-750. Date of Electronic Publication: 2024 Sep 11.
Autor:
Farolfi A; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Gentili N; Outcome Research, IRCCS Istituto Romagnolo per lo studio dei Tumori (IRST) 'Dino Amadori', Meldola, ItalyW., Testoni S; Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Rusconi F; TriNetX, LLC, Cambridge, MA, USA., Massa I; Outcome Research, IRCCS Istituto Romagnolo per lo studio dei Tumori (IRST) 'Dino Amadori', Meldola, ItalyW., Danesi V; Outcome Research, IRCCS Istituto Romagnolo per lo studio dei Tumori (IRST) 'Dino Amadori', Meldola, ItalyW., Altavilla A; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Cursano MC; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Gurioli G; Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Burgio SL; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Ibarburu GH; Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
Publikováno v:
IScience [iScience] 2024 Apr 06; Vol. 27 (5), pp. 109680. Date of Electronic Publication: 2024 Apr 06 (Print Publication: 2024).
Autor:
Pedrouzo-Ulloa, A. (Alberto), Ramon, J. (Jan), Duflot, P. (Patrick), Pérez-González, F. (Fernando), Lilova, S. (Siyanna), Chihani, Z. (Zakaria), Gentili, N. (Nicola), Ulivi, P. (Paola), Hoque, M.A. (Mohammad Ashadul), Mukammel, T. (Twaha), Pritzker, Z. (Zeev), Lemesle, A. (Augustin), Loureiro-Acuña, J. (Jaime), Martı́nez, X. (Xavier), Jiménez-Balsa, G. (Gonzalo)
This paper is an overview of the EU-funded project TRUMPET (https://trumpetproject.eu/), and gives an outline of its scope and main technical aspects and objectives. In recent years, Federated Learning has emerged as a revolutionary privacy-enhancing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4198::b0a5969dab59c1ad79b3a8b584985301
http://hdl.handle.net/20.500.12210/82121
http://hdl.handle.net/20.500.12210/82121
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer Patients.
Autor:
Gentili N; Outcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Balzi W; Outcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Foca F; Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Danesi V; Outcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Altini M; Healthcare Administration, Azienda Unità Sanitaria Locale della Romagna, 48121 Ravenna, Italy., Delmonte A; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Bronte G; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Crinò L; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., De Luigi N; Ospedale di Stato della Repubblica di San Marino, 47893 San Marino City, San Marino., Mariotti M; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Verlicchi A; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Burgio MA; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Roncadori A; Outcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Burke T; MSD Innovation & Development GmbH, 8004 Zurich, Switzerland., Massa I; Outcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy.
Publikováno v:
Cancers [Cancers (Basel)] 2024 Jan 30; Vol. 16 (3). Date of Electronic Publication: 2024 Jan 30.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Bertoni L; Healthcare Administration, IRCCS-Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori'- Irst, Meldola, Italy., Roncadori A; Outcome Research, Healthcare Administration, IRCCS-Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori'- Irst, Meldola, Italy., Gentili N; Outcome Research, Healthcare Administration, IRCCS-Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori'- Irst, Meldola, Italy., Danesi V; Outcome Research, Healthcare Administration, IRCCS-Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori'- Irst, Meldola, Italy., Massa I; Outcome Research, Healthcare Administration, IRCCS-Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori'- Irst, Meldola, Italy., Nanni O; Unit of Biostatistics and Clinical Trials, IRCCS-Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori'- Irst, Meldola, Italy., Altini M; Healthcare Administration, Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy., Gabutti G; Department of Medical Sciences, Università di Ferrara, Ferrara, Italy., Montella MT; Healthcare Administration, IRCCS-Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori'- Irst, Meldola, Italy.
Publikováno v:
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2022 Dec 31; Vol. 18 (1), pp. 1978795. Date of Electronic Publication: 2021 Oct 06.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Danesi V; Outcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Massa I; Outcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Foca F; Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Delmonte A; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Crinò L; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Bronte G; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Ragonesi M; Nursing Service, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Maltoni R; Outcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Manunta S; AULSS5, UOC Oncologia, Ospedale Santa Maria della Misericordia, 45100 Rovigo, Italy., Cravero P; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Andrikou K; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Priano I; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Balzi W; Outcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Gentili N; Outcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', 47014 Meldola, Italy., Burke T; Center for Observational and Real World Evidence, Merck & Co Inc., Kenilworth, NJ 07033, USA., Altini M; Healthcare Administration, Azienda Unità Sanitaria Locale della Romagna, 48121 Ravenna, Italy.
Publikováno v:
Cancers [Cancers (Basel)] 2022 Sep 15; Vol. 14 (18). Date of Electronic Publication: 2022 Sep 15.